SAN DIEGO, March 21, 2012 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today its continued focus on contributing to scientific research in the public domain. The company published research on new therapies in diabetes in nine scientific journals last year and one of its key scientists Prof. Andrew Krentz has authored two textbooks on drug therapy for type 2 diabetes, due to publish this summer.
“We are in a notable position of having been involved in clinical research in almost every promising diabetes-related therapy and in all key anti-diabetic drug categories, benefiting diabetes research as a whole,” said Dr. Marcus Hompesch, Profil Institute CEO. “Profil Institute’s scientists hail from the world’s most renowned institutes and universities focused on diabetes and other metabolic disorders, and we believe strongly in continuing to contribute to the advancement of scientific research in the public domain.”
A list of the company’s most recent publications is available on Profil Institute’s website www.profilinstitute.com under Scientific Expertise with abstracts or full articles available at the US National Library of Medicine’s website www.pubmed.gov.
Scientific journals include Journal of Diabetes Science and Technology; Diabetes Technology and Therapeutics; Diabetes, Obesity and Metabolism; Diabetes Care; and Treatment Strategies Diabetes.
The two textbooks Drug Therapy for Type 2 Diabetes (London: Adis, 2012, in press) and Pharmacotherapy for Type 2 Diabetes (London: Royal Society of Medicine Press, 2012, in press) are authored by Prof. Andrew Krentz, Profil Institute’s Senior Director of Scientific Services.
The textbooks present detailed coverage of established glucose-lowering drugs and recently-introduced therapy options for type 2 diabetes. Most notably for physicians, the textbooks discuss how to integrate newer drugs in the context of established drug therapy, guidelines and treatment algorithms. Both textbooks are expected to publish later this summer.
About Profil® Institute for Clinical Research, Inc.
Profil Institute’s advances in early phase drug research and its specific focus on diabetes, obesity and cardiometabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.
To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 175 clinical studies since the company’s inception in 2004. Contributing to Profil Institute’s success is that the company is recognized as the leader in automated glucose clamps, considered the “Gold Standard” for the evaluation of anti-diabetic drugs and devices. The company’s key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.
SOURCE Profil Institute for Clinical Research, Inc.
